Pharmaceuticals

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

After halting all R&D, PCI Biotech proposes dissolution and delisting, marking the end for its novel drug delivery platform and a warning for investors.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

With stellar trial data and a fast-tracked FDA submission, CG Oncology prepares for a pivotal presentation at the TD Cowen Health Care Conference.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

A new EU directive to clean wastewater could make essential generic medicines unprofitable, sparking fears of widespread shortages across the continent.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

Arrotex secures rights to an innovative, FDA-approved nanotech eye drop, promising faster, simpler recovery for thousands of surgical patients.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

Sai Life Sciences' plan to hire 700+ professionals underscores a global shift, positioning India as a critical hub for pharmaceutical R&D and manufacturing.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A renewed deal between Inmar Intelligence and Premier, Inc. highlights the vital, unseen role of reverse logistics in pharmacy finance, compliance, and safety.

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.